Figure 1. Structures of Immunophilin Ligands
and trans conformations, an action that should influence is to form a drug-immunophilin complex that inhibits the calcineurin phosphatase activity and prevents nuclear protein folding (Fischer et al., 1989; Takahashi et al., 1989) . CsA inhibits this peptidyl prolyl isomerase, or translocation of the NF-ATs (Figure 2 ). Rapamycin Inhibits a Novel Signaling Pathway rotamase, activity at nanomolar concentrations. FKBP12 also possesses rotamase activity, which is inhibited by that Regulates Protein Translation How can rapamycin bind to FKBP12 yet differ from FK506 and rapamycin (Harding et al., 1989; Siekierka et al., 1989a) . Thus, rotamase inhibition might appear FK506 in its immunologic effects? The observation that rapamycin could compete with FK506 for its intracellular fundamental to immunosuppression.
However, numerous compounds that bind to the imreceptor led to the discovery that rapamycin and FK506 shared FKBP12 as a common receptor (Bierer et al., munophilins and inhibit their rotamase activity lack immunosuppressant effects (Bierer et al., 1990b; Dumont 1990a; Dumont et al., 1990a Dumont et al., , 1990b . Unlike FK506, the FKBP12-rapamycin complex does not bind or inhibit et al., 1992) . Moreover, these immunosuppressive drugs typically act at low nanomolar concentrations, whereas calcineurin. Because low nanomolar concentrations of rapamycin block signaling in cells that contain microtissue levels of some immunophilins are almost micromolar, so that in intact tissues, only a very small portion molar concentrations of FKBP12, most investigators assume that rapamycin, like FK506, acts by a gainof rotamase activity would be inhibited . In principle, these immunosuppressants might act via of-function mechanism, with the FKBP12-rapamycin complex binding to another target protein. one of the immunophilins whose tissue density is very low. Alternatively, one might hypothesize a "gain-ofTo seek such a target, we and others looked for proteins that might bind to FKBP12 only in the presence function" mechanism whereby the drug-immunophilin complex would bind to a second protein that could not of rapamycin. We identified two proteins that interact selectively with radiolabeled FKBP12 only when rapabe influenced by the immunophilin or drug alone.
The first drug-immunophilin target was discovered mycin is present and cloned the cDNA for the larger one, designated rapamycin and FKBP12 target 1 (RAFT1) by Liu et al. (1991) and Friedman and Weissman (1991) , who showed that complexes of cyclophilin A-CsA and (Sabatini et al., 1994) . Independently, Schreiber and colleagues (Brown et al., 1994) cloned the cDNA for the FKBP12-FK506 bind to calcineurin, a calcium/calmodulin-activated protein phosphatase, and inhibit its activsame protein and called it FKBP and rapamycin associated protein (FRAP). RAFT1/FRAP has subsequently ity. The relative potencies of FK506, CsA, and related compounds in inhibiting calcineurin correlate closely been identified by other workers (Chiu et al., 1994; Sabers et al., 1995) . RAFT1 is the mammalian homolog of with their immunosuppressive potencies, suggesting a role for calcineurin in their immunosuppressive action.
two yeast proteins, Tor1 and Tor2 (target of rapamycin) (Heitman et al., 1991; Kunz et al., 1993) , which when In T cells, an important calcineurin substrate is the phosphorylated form of the transcription factor family, numutated confer resistance to the lethal effects of rapamycin in yeast. Accordingly, RAFT1 is also referred to clear factor of activated T cells (NF-AT). The NF-ATs stimulate the transcription of a number of genes required as mammalian Tor (mTor). RAFT1 contains a C-terminal area that is homologous to the kinase domain of phosfor T cell proliferation, notably IL-2 (Tocci et al., 1989) . However, the NF-AT protein cannot enter the nucleus phatidylinositol-3 kinase (PI-3 kinase) (Brown et al., 1994; Sabatini et al., 1994) and is the founding mammaunless it is dephosphorylated by calcineurin. Therefore, the mechanism of immunosuppression by these drugs lian member of a new family of proteins that includes Upon engaging the antigen-MHC complex in the appropriate context, the activated T cell receptor initiates a cascade of intracellular signaling events that leads to an influx of calcium into the cytosplasm. The elevated intracellular calcium concentration activates the calcium-sensitive protein phosphatase calcineurin by promoting the binding of the calcium/calmodulin complex to the phosphatase. Active calcineurin dephosphorylates the NF-AT, allowing its translocation into the nucleus, where it upregulates the transcription of several cytokine genes, including IL-2. The presence of either the FKBP12-FK506 or the cyclophilin cyclophilin-CsA (Cyp-CsA) complex inhibits the calcineurin-dependent dephosphorylation of NF-AT.
the DNA-activated protein kinase (DNA-PKcs) (Hartley S6 protein of the 40S subunit. Phosphorylation of the S6 protein increases the ribosome's affinity for a subset et al., 1995) and the protein product of the gene that is disrupted in the disease ataxia telangiectasia (ATM) of mRNAs containing significant 5Ј secondary structure or polypyrimidine tracts (Jefferies et al., 1994; Terada (Lavin et al., 1995) . While RAFT1 and the yeast TOR proteins have lipid kinase activity (Cardenas and Heitet al., 1994) . Rapamycin blocks S6 phosphorylation by p70 S6 kinase (Chung et al., 1992; Kuo et al., 1992 Kuo et al., ). man, 1995 Sabatini et al., 1995) , it is unclear whether this enzymatic activity is intrinsic to RAFT1/Tor or a Moreover, we found that the p70 S6 kinase is directly phosphorylated by RAFT1, and this phosphorylation can tightly associated lipid kinase.
Rapamycin's interference with protein translation is be inhibited by rapamycin (Burnett et al., 1998a) . Therefore, one mechanism of translational inhibition by rapathought to be the mechanism for its antimitotic activity. The drug blocks several steps in growth factor actions mycin is directly inhibiting RAFT1-dependent ribosomal phosphorylation. on translational regulators. Recent work in our laboratory and others' has demonstrated that RAFT1 functions All mRNAs have a 7-methylguanosine cap structure at their 5Ј-end that mediates translation initiation. This as a protein kinase that phosphorylates several key regulators of protein translation (Figure 3) . cap is bound by eukaryotic initiation factor (eIF-4E). To initiate translation, eIF-4E must also bind the eIF-4G One of the shared effects of mitogenic stimuli is a rapid phosphorylation of the ribosome, primarily on the protein and thereby recruit the eIF-4F complex to the The ability of rapamycin to inhibit protein translation has been well studied in two substrates of RAFT1, p70 S6 kinase and eukaryotic initiation factor 4E-binding protein 1(eIF 4E-BP1). mRNA (Sonenberg, 1996) . This process can be inhibited cells. Parallel studies of calcineurin mRNA and protein densities reveal very similar localizations throughout the by the unphosphorylated form of the 4E binding protein (4E-BP1), also known as Phas-1. When 4E-BP1 is phosbrain, implying a physiological link between calcineurin and FKBP12. phorylated by RAFT1 (Brunn et al., 1997; Burnett et al., 1998a) and other mitogen-stimulated kinases, it can no Cyclophilin localizations also resemble calcineurin. Both are highly concentrated in cerebellar granule cells longer bind to eIF-4E, and the translation initiation complex is assembled (Beretta et al., 1996; von Manteuffel and in the CA1 area of the hippocampus, as well as in the olfactory bulb (Goldner and Patrick, 1996) . Howet al., 1996) . Rapamycin inhibits the phosphorylation of 4E-BP1 by RAFT1 and therefore inhibits the initiation of ever, calcineurin localizations overall resemble those of FKBP12 more than cyclophilin. For instance, calcineurin protein translation (Brunn et al., 1997; Burnett et al., 1998a) . and FKBP12 are both highly concentrated in the caudate, nucleus accumbens, and olfactory tubercle, which In cellular homogenates, RAFT1 is partially soluble and partially particulate, and so its activity might be display only modest levels of cyclophilin (Dawson et al., 1994) . regulated by translocation between the cytoplasm and the membrane. In a yeast two-hybrid analysis, we disAs colocalizations often imply physiologic association, cain (calcineurin inhibitor), a recently identified calcovered that RAFT1 interacts with gephyrin , first identified as a protein that copurifies with cineurin inhibiting protein, appears to be an important regulator of this enzyme (Lai et al., 1998) . Cain was the receptor for the neurotransmitter glycine (Betz et al., 1994) . Gephyrin interacts with a domain of RAFT1 discovered as a protein that binds calcineurin alone or in complexes with FKBP12 in the yeast two-hybrid that displays considerable homology to the gephyrin binding site of the glycine receptor. The binding of system and other binding studies. Cain is a large cytosolic protein, about 240 kDa, without significant homol-RAFT1 to gephyrin is crucial for its phosphorylation of p70 S6 kinase and 4E-BP1 because mutations in RAFT1 ogy to any known proteins. A 38 amino acid segment in the C-terminal region of cain accounts for all of its that block its binding to gephyrin also block its ability to regulate p70 S6 kinase and 4E-BP1 (Sabatini et al., calcineurin binding activity. Accordingly, the large remaining portion of cain might serve a scaffolding role, 1996).
analogous to A kinase anchoring protein (AKAP)-79, Neuronal Localizations of Immunophilins Establish which binds calcineurin, as well as protein kinase C and a Physiologic Link to Calcineurin cAMP-dependent protein kinase (Coghlan et al., 1995; The discovery that immunosuppressants bind with high Klauck et al., 1996) . Microscopic localizations of cain affinity to immunophilins and stimulate interactions with mRNA are virtually superimposable on those of calcalcineurin implies the existence of endogenous ligands cineurin, with more impressive colocalization than befor the immunophilins that somehow influence caltween calcineurin and FKBP12. Cain inhibits calcineurin cineurin activity. However, no evidence has yet been noncompetitively at submicromolar concentrations more obtained for an endogenous small molecule ligand for potently than AKAP-79. Conceivably, cain may serve as immunophilins. Moreover, the fact that immunosupa docking site for calcineurin, maintaining the phosphapressant drugs influence calcineurin activity does not tase in an inactive form. According to this model, the necessarily mean that immunophilins normally interact release of calcineurin from cain would provide calciumwith calcineurin. Evidence for a physiological associasensitive phosphatase activity to specific intracellular tion of immunophilins and calcineurin has come from targets. studies of brain localizations. Initial studies monitoring [ Interactions of immunophilins with calcineurin in the presence of immunosuppressive drugs do not establish the spleen, heart, kidney, liver, and lung. In contrast, binding levels in the brain are up to 50 times higher than physiologic roles for mammalian immunophilins. Immunophilins are found in bacteria, yeast, and plants, as in any peripheral tissue, depending on the brain region examined (Steiner et al., 1992; Dawson et al., 1994) . The well as in mammals and in cells lacking calcineurin. This implies the immunophilins associate with other proteins. more than 10-fold variation in [ 3 H]FK506 binding levels among various brain regions has been corroborated by One such protein is the ryanodine receptor, a major intracellular calcium channel that mediates calciumlocalization of its mRNA by in situ hybridization (Steiner et al., 1992) . FKBP12 is sufficiently enriched in neurons induced calcium release. Highly purified preparations of the ryanodine receptor (RyR) consistently retain a very that extraneuronal levels are not detected routinely. Highest densities of the FKBP12 transcript occur in the small protein "contaminant," which turned out to be FKBP12 (Jayaraman et al., 1992) . The other major intracorpus striatum, with comparable levels evident in the substantia nigra zona compacta (Dawson et al., 1994) . cellular calcium channel is the inositol 1,4,5-trisphosphate receptor (IP3R). Extensively purified IP3R preparaLesioning studies indicate that these localizations reflect a very high FKBP12 content in the descending tions also contain tightly associated FKBP12 (Cameron et al., 1995a) . striatonigral pathway. High levels of FKBP12 are found in the hippocampus, with an enrichment in the CA1 layer.
What might be the function of the FKBP12 contained in IP 3 and ryanodine receptor preparations? Biophysical In the cerebral cortex, FKBP12 is most prominent in superficial layers, while in the cerebellum it is present in studies of the RyR by Marks and associates (Brillantes et al., 1994) reveal that FKBP12 is required for physiologic all cellular layers, with the highest density in the Purkinje The calcium-releasing channels RyR and IP3R are physiologically complexed with FKBP12 and calcineurin. FKBP12 stabilizes calcium channels by decreasing the probability of spontaneous opening and by reducing the frequency of subconductance states, in which where the channels are partially open. Calcineurin, anchored to the calcium channels via FKBP12, modulates the calcium flux by changing the phosphorylation state of IP 3R in a calcium-dependent manner. Stripping the FKBP12-calcineurin complex from calcium channels with FK506 leads to leaky RyR and IP 3R, which exhibit increased probability of channel opening and presence of multiple subconductance states. calcium release. When FKBP12 is dissociated from the AKAP-79 (Coghlan et al., 1995; Klauck et al., 1996) . AKAP-79 exists in a complex together with PKA and RyR by the addition of FK506 or rapamycin, multiple subconductance states and a higher probability of calcineurin. Strikingly, the calcineurin binding domain in AKAP-79 resembles the domain in FKBP12 that binds opening are observed. FKBP12 stabilizes the RyR and prevents calcium leakage in the absence of receptor to calcineurin, supporting a similar scaffolding role for the two proteins. How does the IP3R bind to FKBP12? activation. Similarly, stripping FKBP12 from the IP3R by treatment with FK506 results in an increased flux of Yeast two-hybrid studies have identified the leucineproline 1400-1401 dipeptide as the site of interactions calcium in response to lower concentrations of IP3R (Cameron et al., 1995a) .
with FKBP12 (Cameron et al., 1997) . Analogous leucylprolyl or valyl-prolyl sequences are conserved in all A physiologic role for the interaction of FKBP12 and RyR has been established using mice with a targeted subtypes of the IP3R, the RyR, and the type 1 TGF␤ receptors, which all interact with FKBP12, indicating deletion of FKBP12 (Shou et al., 1998) . Disturbances of calcium conductance of RyRs in skeletal muscle memthat this sequence is likely a universal ligand selective for FKBP12 binding. FKBP12 may be more important branes from FKBP12-deficient mice resemble those of purified RyRs in the absence of FKBP12. The defect in as a scaffold linking proteins together than as a peptide prolyl isomerase enzyme mediating protein folding. Decalcium conductance has apparent clinical relevance, as FKBP12 deficient mice die prior to, or a few weeks spite extensive investigations, only modest evidence has accumulated for a physiological role of the immuafter, birth, with severe cardiomyopathy resembling the cardiac abnormalities of patients treated with FK506 nophilins in regulating protein folding. Molecular biological characterizations indicate that (Atkison et al., 1995) .
The FKBP12 complex with the IP3 and ryanodine rethe IP3R mimics the role of FK506 in promoting the association of calcineurin and FKBP12 (Cameron et al., 1997) . ceptors also includes calcineurin. Calcineurin copurifies with both of these calcium channels, even after extenThe chemical structure of FK506 resembles a leucylproline dipeptide . Taken together, sive purification procedures (Cameron et al., 1995b) . The IP 3 R (Ferris et al., 1991) is phosphorylated by several these data support the notion that IP 3 and ryanodine receptors are "endogenous ligands" for FKBP12. This kinases, including protein kinase C (PKC), protein kinase A (PKA), and calcium-calmodulin-dependent kinase II would contrast with the common conception that such endogenous ligands should be small molecules, analo-(CaM-K II). The IP 3 R also autophosphorylates (Ferris et al., 1992) . Calcineurin, which copurifies with the IP 3 R, gous to the enkephalin pentapeptides mimicking morphine at the opiate receptor (Snyder, 1977) . Since the modulates both its phosphorylation state and its ability to conduct calcium (Cameron et al., 1995b) . Calcineurin IP 3 R is about 200 times larger than FKBP12, perhaps the optimal conceptualization would be of FKBP12 as inhibition augments IP 3 R phosphorylation, especially in response to PKC. Increased phosphorylation by PKC a ligand for the IP3R rather than vice versa. Another protein that binds to FKBP12 in a pattern and CaM-K II renders IP3 more potent in releasing calcium, whereas PKA phosphorylation makes the receptor resembling the IP3 and ryanodine receptors is the type I receptor for transforming growth factor-␤ (TGF␤). TGF␤ less sensitive to IP3 (Ferris et al., 1991) . Thus, FKBP12 appears to function as a calcineurin-anchoring protein signaling is transduced by binding and juxtaposing the type I and type II TGF␤ receptors, allowing the constitufor the IP3R, with PKC participating in the complex (Figure 4) . Such a complex would facilitate rapid cycles tive kinase activity of type II to phosphorylate and activate the type I receptor. Downstream effects of TGF␤ of phosphorylation and dephosphorylation, leading to corresponding increased and decreased calcium resignaling lead to diverse biological consequences in development and tumorogenesis (Massagué , 1996) . In lease.
The FKBP12-IP 3 R-calcineurin complex is reminiscent the nervous system, TGF␤ induces long-term synaptic facilitation (Zhang et al., 1997), protects hippocampal of those associated with the A kinase-anchoring protein Influx of calcium through NMDA receptors activates the calcium-sensitive protein phosphatase calcineurin by stimulating its binding to the calcium/calmodulin complex. Activated calcineurin dephosphorylates nNOS, increasing its catalytic activity. The subsequent increase in NO formation can lead to neurotoxicity and increased neurotransmitter release. FK506 and CsA protect neurons against NMDA neurotoxicity by inhibiting the calcineurin-dependent activation of nNOS. These drugs may also reduce the NMDAstimulated neurotransmitter release by the same mechanism.
neurons from ischemic damage and ␤-amyloid peptideinhibits NOS catalytic activity in cells, as would be expected from the increased phosphorylation of NOS induced toxicity (Henrich-Noack et al., 1996; Ren and Flanders, 1996) , and promotes axonal caused by FK506-mediated calcineurin inhibition. The excitatory neurotransmitter glutamate, acting through regeneration (Abe et al., 1996) . Using the yeast twohybrid system, several groups identified an interaction N-methyl-D-aspartate (NMDA) receptors, activates nNOS, resulting in increased cGMP production secondary to between FKBP12 and the type I TGF␤ receptor (Wang et al., 1994; Okadome et al., 1996) . This interaction involves nitric oxide (NO) activation of guanylyl cyclase (Snyder, 1992) . While glutamate in low levels acts as a neurothe leucine-proline 193-194 dipeptide of the type I TGF␤ receptor (Charng et al., 1996) , analogous to the intertransmitter, high concentrations of glutamate released in vascular stroke cause neurotoxicity by stimulation of actions observed between FKBP12 and the calcium channels described above. Evidence demonstrating the NMDA receptors (Choi, 1988) . The involvement of NO in glutamate-mediated excitotoxicity is based on findings physiologic significance of this interaction has been conflicting. While some investigators observed no sigthat NOS inhibitors and nNOS gene knockout substantially reduce neural damage in NMDA-treated cultures nificant contribution to TGF␤ signaling by FKBP12 (Charng et al., 1996; Okadome et al., 1996) , others have demonand following vascular stroke (Yun et al., 1996) . These findings suggest that FK506, by inhibiting calcineurin, strated that disruption of the association between FKBP12 and type I TGF␤ receptor leads to enhanced signaling decreases NO formation ( Figure 5 ). FK506 does diminish the elevated cGMP levels following NMDA treatment of through the receptor (Wang et al., 1996; Chen et al., cortical cultures, and low nanomolar concentrations of 1997). In mice with targeted deletion of the gene for FK506 or CsA block NMDA neurotoxicity in cortical cul-FKBP12, TGF␤ signaling appears normal (Shou et al., tures . 1998). However, all parameters of TGF␤ signaling were Based on these findings, Sharkey and Butcher (1994) not evaluated, and mechanisms compensating for the demonstrated that FK506 administration diminishes neuloss of FKBP12 may have arisen during embryonic deral tissue damage following middle cerebral artery ocvelopment.
clusion in rats. The observation that these effects are The yeast two-hybrid system has also been employed blocked by rapamycin suggests a role for calcineurin to identify another protein that binds FKBP12, desiginhibition in neuroprotection. Consistent with this hynated FKBP-associated protein-48 (FAP-48) (Chambraud pothesis, antistroke effects have also been reported et al., 1996) . FAP-48 associates with FKBP59, as well with CsA (Coimbra et al., 1997, Soc. Neurosci., abas FKBP12, but the physiologic significance of these stract). Recently, Butcher et al. (1997) observed that associations is unclear.
while the administration of either FK506 or CsA can Immunophilin Ligands Prevent Neurotoxicity reduce ischemic brain damage in rats, these drugs cannot protect animals against quinolinate-induced excitoand Vascular Stroke Damage The notion that immunophilins play a role in neurotoxicity (Butcher et al., 1997) . This suggests that the in vivo neuroprotective effects of immunophilin ligands toxicity came from initial studies of calcineurin substrates. Treating brain homogenates with FK506 resulted may involve mechanisms distinct from NMDA-mediated signaling pathways. in increased phosphorylation levels of numerous proteins, one of which was neuronal nitric oxide synthase
The neuroprotective actions of immunophilin ligands extend to other forms of neurotoxicity. CsA and FK506 (nNOS) . nNOS can be phosphorylated by several kinases, including PKC, resulting in inhiderivatives provide pronounced protection against neurotoxicity elicited by the ␤-amyloid peptide (Pasinetti bition of catalytic activity (Bredt et al., 1992 ). FK506 Figure 6 . Regulation of Neurotransmitter Release by Dynamin I and Immunophilin Ligands Cellular depolarization opens voltage-gated calcium channels and increases intracellular calcium concentration. Intracellular calcium activates both PKC and calcineurin, which exert opposing effects on the phosphorylation state of the GTPase dynamin I. Phosphorylation of dynamin I by PKC increases its GTPase activity, leading to increased neurotransmitter release secondary to an increased rate of vesicle recycling. Inhibition of calcineurin by either Cyp-CsA or FKBP12-FK506 complex leads to enhanced phosphorylation of dynamin I and a subsequent increase in depolarization-evoked neurotransmitter release.
and Aisen, 1997, Soc. Neurosci., abstract) and serum activity (Robinson et al., 1993) . Dynamin I is also a caldeprivation of cortical cultures (Hugon et al., 1997, Soc. cineurin substrate (Liu et al., 1994) ; accordingly, CsA and Neurosci., abstract).
FK520 treatment enhance dynamin I phosphorylation The ability of immunophilin ligands to block neurotox-( Figure 6 ). icity in numerous models of important neurological disThus, immunophilins and their ligands probably regueases may have clinical relevance. Drugs such as FK506 late neurotransmitter release by modulating calcineurin penetrate the blood-brain barrier reasonably well and activity. Whether transmitter release is increased or deare already commercially marketed, so therapeutic evalcreased in a given circumstance depends on the relative uation may be relatively straightforward.
prominence of individual calcineurin substrates such as nNOS or dynamin I. Modulation by immunophilins of calcineurin activity in vivo may be determined by endogImmunophilins Regulate Neurotransmitter Release enous ligands of the immunophilins such as the IP 3 and Inhibition of NOS activity by immunophilin ligands may ryanodine receptors. Other endogenous proteins that also account for influences on neurotransmitter release. directly regulate calcineurin activity, such as cain and Low nanomolar concentrations of FK506 reduce gluta-AKAP-79, may also be involved in the modulation of mate release from NMDA-stimulated striatal synaptosomes and also diminish acetylcholine and dopamine neurotransmitter release. release from PC12 cells following differentiation elicited by nerve growth factor (NGF) (Steiner et al., 1996) . A Immunophilins Mediate Nerve Regeneration concentration of FK506 as low as 0.1 nM is effective in Early work examining immunophilins in the nervous sys-PC12 cells. Inhibitors of NOS also block neurotransmittem provided several clues to a link between neuronal ter release (Hirsch et al., 1993) . Since inhibition of calregeneration and immunophilins. The relatively high excineurin leads to decreased NOS activity secondary to pression levels of FKBP12 in peripheral nerves and its enhanced phosphorylation, inhibition of neurotransmitpresence in the growth cones of developing neurons ter release observed in the aforementioned experimensuggested a potential role in nerve growth. Additionally, tal systems in the presence of FK506 and CsA likely lesions of the sciatic or facial nerve markedly augment results from reduced NO formation ( Figure 5) .
mRNA levels for FKBP12 in the facial and lumbar nuclei, In contrast, in synaptosomes depolarized by the porespectively (Lyons et al., 1995) . tassium channel blocker 4-aminopyridine, treatment
In PC12 cells, FK506 substantially enhances neurite with CsA or FK520, an analog of FK506 that also inhibits outgrowth, with half-maximal effects occurring at about calcineurin, augments the release of glutamate (Nichols 0.1 nM (Lyons et al., 1994) . Rapamycin is neurotrophic et al., 1994) . In this system, the stimulation of neurofor PC12 cells with similar potency (Steiner et al., 1997a) . transmitter release in the presence of immunophilin li-FK506 stimulates PC12 cells' neurite outgrowth only in gands parallels increased phosphorylation of a promithe presence of NGF and enhances the neurotrophic nent synaptic protein, dynamin I. Dynamin I is a GTPase potency of NGF about 10-fold (Lyons et al., 1994) . In whose activity regulates the rate of synaptic vesicle resensory ganglia, FK506 enhances neurite outgrowth in cycling, and hence the rate of neurotransmitter release the absence of exogenous NGF, perhaps because (De Camilli and Takei, 1996; Urrutia et al., 1997). Phosphorylation of dynamin I by PKC activates its GTPase Schwann cells in the ganglia synthesize the necessary small amounts of neurotrophic molecules. Concentraand related compounds more suitable candidates for treating neurological diseases. tions of FK506 in the picomolar range produce detectable stimulation in rat (Lyons et al., 1994) and chick
The neurotrophic effects of the immunophilin ligands are demonstrable in models of neurologic disability in dorsal root ganglia (Steiner et al., 1997a) .
Initial efforts to explain the neurotrophic effects fointact animals. FK506 stimulates regrowth of damaged sciatic nerves and functional recovery (Gold et al., 1994 , cused on calcineurin substrates, especially GAP-43. GAP-43 (growth associated protein of 43 kDa) is se-1995; Steiner et al., 1997a) . Nonimmunosuppressive derivatives are also effective. Thus, GPI-1046 (Steiner et lectively localized to developing or regenerating neurons (Basi et al., 1987) . Phosphorylation of GAP-43 is al., 1997b), V-10,367 (Gold et al., 1997) , and L-685,818 (Steiner et al., 1997a) , a nonimmunosuppressive FK506 associated with enhanced function, and GAP-43 is a calcineurin substrate whose phosphorylated levels are derivative, augment regrowth of damaged sciatic nerves. GPI-1046 also stimulates regrowth of damaged neurons increased by FK506 treatment (Steiner et al., 1992) . Moreover, following facial nerve crush, both in the brain. Following lesion of serotonin neurons with P-chloroamphetamine, animals receiving GPI-1046 disand FKBP12 mRNA levels in the facial nucleus increase dramatically with similar time courses (Lyons et al., play double the density of serotonin-positive neuronal fibers in the cerebral cortex, compared with untreated 1995).
Strong evidence that calcineurin inhibition does not animals (Steiner et al., 1997b) . GPI-1046 similarly stimulates the regrowth of cholinergic neurons in the brain mediate neurotrophic effects comes from studies with close structural derivatives of FK506, CsA, and rapafollowing fimbria-fornix lesions (Guo et al., 1997, Soc. Neurosci., abstract) . mycin that bind with high affinity to the immunophilins. However, complexes of these derivatives with the immuThe most extensive central nervous system studies have been conducted with dopaminergic neurons. Lenophilins fail to bind or inhibit calcineurin and are not immunosuppressive (Steiner et al., 1997a) . These nonsions with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) elicit massive immunosuppressive derivatives are neurotrophic for PC12 cells and sensory ganglia with potencies and maxdestruction of nigral dopaminergic neurons (Gerlach et al., 1991) . These are the same neurons that degenerate imal effects similar to their immunosuppressive analogs.
Using principles of rational drug design, novel comin patients with Parkinson's disease, making MPTP and 6-OHDA treatment experimental paradigms for the study pounds that can bind FKBP12, but not calcineurin, have been synthesized. One such compound, 3-(3-pyridyl)-of this disorder. Treatment with GPI-1046 before, during, or after the MPTP lesions substantially restores the dam-1-propyl (2S) -1-(3,3 -dimethyl-1, 2 -dioxopentyl)-2-pyrrolidinedinecarboxylate (GPI-1046) (Figure 1 ), inhibits aged dopamine neurons, as demonstrated by increased striatal tyrosine hydroxylase staining and reversal of FKBP12 rotamase activity with a Ki of 7.5 nM and fails to inhibit T cell proliferation at concentrations up to haloperidol-induced catalepsy and akinesia (Steiner et al., 1997b; Steiner et al., 1997, Soc. Neurosci., abstract) . 10 M (Steiner et al., 1997b) . GPI-1046 elicits neurite outgrowth in chick sensory ganglia at 1 pM concentraIn rats lesioned with unilateral intranigral 6-OHDA administration, GPI-1046 elicits both morphological and tion with 50% maximal effect at 58 pM (Figure 7 ). Similar findings have been observed with other nonimmufunctional recovery, with increased striatal catecholamine levels and a reduction in amphetamine-induced nosuppressive FK506 analogs such as V-10,367 (Gold et al., 1997 
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